23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Corporate solution
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Welcome to our Corporate client solution

    Here you can administrate your corporate solutions users.

  • Welcome to your subscription for Life Science Focus

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Focus.

  • Click here to go to sign-up
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Try Life Science Focus now
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement
Interview

Swedish firm makes progress on antiviral treatment

A compound developed by Swedish company Virenc has shown promising results against SARS-CoV-2 in an advanced model of human airways. The findings mark a step forward in efforts to develop a treatment that could act against multiple viruses.
Advertisement

Researchers Hazem Khalaf and Torbjörn Bengtsson, the founders of Virenc, have developed and patented a compound based on the antiviral peptides PLNC8ab. The peptides target viruses in a different way from many existing treatments.

Earlier this year, Virenc began collaborating with Niklas Arnberg, professor of virology at Umeå University. The peptides have now been tested in an advanced 3D model of human airways.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.063|